Blends

Cagrilintide / Semaglutide

Prepared by the ezGLP team. Sources last checked September 5, 2026.

Also known as CagriSema, Cagrilintide + Semaglutide

Routes represented in the knowledgebase: Subcutaneous (SubQ).

Educational overview

Cagrilintide / Semaglutide is listed in the ezGLP knowledgebase under Blends. Evidence and regulatory status can vary by formulation, route, and jurisdiction.

Category: Blends
Routes represented: Subcutaneous (SubQ)
Storage context: Follow the dispensed product label; storage and in-use limits vary by brand and formulation.

Published literature

Safety evidence

Common or reported: nausea, vomiting, diarrhea, constipation, abdominal pain or indigestion, decreased appetite.

Serious or important: pancreatitis, gallbladder disease, dehydration-related kidney injury, severe GI reactions, hypoglycemia with insulin or secretagogues, hypersensitivity.

Product labels also carry thyroid C-cell tumor warnings.

Safety evidence source

Interaction evidence

These are general, pairwise evidence notes. Green identifies the potential-synergy category, while Lv3/Lv2/Lv1 communicates evidence strength; it does not guarantee benefit or cancel a safety warning.

With insulin or insulin secretagogues

Safety flag

Combined glucose lowering increases hypoglycemia risk, including severe hypoglycemia.

Interaction evidence source

With another GLP-1 receptor agonist

Safety flag

Weight-management labels say coadministration with the same active ingredient or another GLP-1 receptor agonist is not recommended.

Interaction evidence source

With narrow-index or threshold-dependent oral medicines

Safety flag

Delayed gastric emptying can alter the timing or extent of oral-drug absorption.

Interaction evidence source

With Pramlintide

Safety flag

Additive gastric-emptying delay, GI intolerance, and glucose lowering are plausible; a broad clinical contraindication is not established.

Interaction evidence source

With semaglutide

Complementary evidenceLv3

Randomized human trials directly studied co-administered cagrilintide and semaglutide and found complementary weight and glycemic effects.

Interaction evidence sourcePhase 3 trialFDA unapproved GLP-1 warning

With metformin

Complementary evidenceLv3

Semaglutide, tirzepatide, and liraglutide have been studied as add-on therapy to stable metformin, with complementary glucose and weight effects in type 2 diabetes.

Interaction evidence sourceTirzepatide trialLiraglutide trial

Summarised from published literature for reference only, with citations to the source. Evidence is graded as reported and is not a recommendation to combine, dose, or use any compound.

For personal tracking and education only. Not medical advice, diagnosis, or treatment, and not a medical device. Peptides may be prescription-only or unapproved where you live — consult a licensed healthcare professional.